DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for Charcot-Marie-Tooth disease type 4B3 — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCharcot-Marie-Tooth disease type 4B3 maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for charcot-marie-tooth disease type 4b3 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
A 2018 review of Charcot–Marie–Tooth disease (CMT) states that as of that date there is still no effective therapy. The review mentions a large-scale trial of PXT3003 as a potential source of hope for curative therapies, but provides no efficacy data, no sample sizes, and no survival or response rates. The review covers the period 2012–2016 and notes that no effective treatment existed then.
A 2022 case report describes a novel mutation in the MPZ gene causing early-onset but slow-progressive CMT in a Russian family. The report does not test any drug, does not report any treatment outcomes, and does not involve drug repurposing. It is a genetic characterisation only.
A 2019 study investigated the RTN4 (Reticulon 4) gene as a potential therapeutic target for axonal regeneration in a family with CMT phenotypes. After sequencing and pathogenicity analysis, the study concluded that the RTN4 gene is not involved in causing Charcot–Marie–Tooth disease type 1. The study did not test any drug and did not report any treatment outcomes.
No abstract in this set reports a drug that has been tested in CMT type 4B3 specifically. No abstract provides any survival, response rate, or sample size for any drug in any CMT subtype. The evidence base for drug repurposing in CMT4B3 remains absent. What is missing is any clinical trial data, any patient stratification by genetic subtype, and any funding directed specifically at this rare form of the disease.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Precision Medicine · 2018 · 0 citations
An Update ON Charcot–Marie–Tooth Diseases
AbstractCharcot–Marie–Tooth disease (CMT) is the most common form of hereditary neuropathy. With the advent of new molecular techniques like NGS, the clinical and genetic spectrum of CMT has been greatly expanded .Our aim is to review the recent research advances in CMT in the last five years (2012-2016), including an update on classification and genetic spectrum, additions to the algorithm for CMT diagnosis and the developments of new animal models and biomarkers. We will also discuss the progress in potential treatments for CMT. Though there is still no effective therapy to date, a number of large-scales new therapeutic trials such as PXT3003 may give hopes for curative therapies.
Sage Journals Data · 2022 · 0 citations · open access
sj-pdf-2-imr-10.1177_03000605221139718 - Supplemental material for Novel mutation in the <i>MPZ</i> gene causes early-onset but slow-progressive Charcot–Marie–Tooth disease in a Russian family: a case report
AbstractSupplemental material, sj-pdf-2-imr-10.1177_03000605221139718 for Novel mutation in the <i>MPZ</i> gene causes early-onset but slow-progressive Charcot–Marie–Tooth disease in a Russian family: a case report by Anastasiya Aleksandrovna Kozina, Natalia Vladimirovna Baryshnikova, Anna Yurievna Ilinskaya, Anna Alexandrovna Kim, Nikolay Alekseevich Plotnikov, Nadezhda Andreevna Pogodina, Ekaterina Ivanovna Surkova, Peter Alekseevich Shatalov and Valery Vladimirovich Ilinsky in Journal of International Medical Research
Journal of the Pakistan Medical Association · 2019 · 0 citations · open access
In-silico and Molecular Analysis of RTN4 as novel therapeutic option for axonal regeneration
AbstractOBJECTIVES: To find interactions of the ligand with axonali nhibitors, and to check the optimum interactions of existing drugs as inhibitors for the protein that hinders the growth of injured neurons. METHODS: The study was conducted at Kongju National University, Korea from May 2016 to March 2017. It consisted of two parts. Molecular analysis and bioinformatics analysis. The study comprised a family of six with Charcot-Marie-Tooth phenotypes, recommended by a neurologist for molecular analysis on the clinical symptoms to find the mutations responsible for the disease. Blood samples were collected from each family member and total deoxyribonucleic acid was extracted and it was analysed for Reticulon 4 gene by sequencing the coding and intronic regions. However, a missense mutation was found on exon 2 of the gene in the proband and the whole family was subsequently analysed. Bioinformatics analysis and docking studies were carried out to investigate the potential behaviour of Reticulon 4 as therapeutic agent. Sequencing analysis was performed to find the pathoegenic variant responsible for Charcot-Marie-Tooth type 1. RESULTS: After checking pathogenicity of the mutation, Reticulon 4 gene was found to be not involved in Charcot- Marie-Tooth disease type 1. CONCLUSIONS: Reticulon 4 gene was not found to be involved in causing Charcot-Marie-Tooth disease type 1.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
